Tradestie Institutional Equity Comparison Engine · Market Close Aug 26, 2026

LYRA vs FBRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FBRX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–0 Matrix Metrics)

FBRX Overall Winner 6-Pillar Tally: LYRA 2 – 3 FBRX (1 Tie) Matrix Metrics: LYRA 0 – 7 FBRX

As of Aug 26, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas FBRX carries 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LYRA vs FBRX
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82
FBRX NASDAQ Head-to-Head Winner
Forte Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$76.99
+0.03% 1D
Market Cap $1.6B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.09β · 3% Vol
Unified Composite Score
52.7 / 100 HOLD
Tech 49.0 Fund 51.0 Flow 62.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (78.3% over 20 days), RSI 85
RSI-14: 84.7 · SMA20: $76.83 · SMA50: $52.74

6-Pillar Scorecard Institutional Category Breakdown (LYRA 2 – 3 FBRX)

Columns: Metric · LYRA · FBRX
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.9x N/M
2. Growth & Scale FBRX
Revenue Growth (YoY) -87.2% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $600,000 N/A
Market Cap $2.3M $1.6B
3. Profitability & Quality FBRX
Gross Margin N/A N/A
Operating Margin -25032.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -404.5% -62.3%
4. Balance Sheet & Cash Flow LYRA
Cash Generation (TTM) -$32M EBITDA -$72M
Cash Flow Margin N/A N/A
Net Cash / Leverage -404.5% ROE $7.52 Book/Sh · -62.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FBRX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 11.1% (3rd %ile)
Put/Call OI Skew N/A 0.77x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LYRA (0) vs FBRX (7)
Institutional Metric LYRA FBRX Criterion Row Edge
Market Capitalization
Scale
$2.3M $1.6B Larger Scale FBRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-87.2% +0.0% Higher Growth FBRX
Operating Margin (TTM)
Profitability
-25032.0% 0.0% Higher Margin FBRX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-404.5% -62.3% Higher ROE FBRX
52-Week Range Position
Momentum
1% ($0–$38) 100% ($10–$77) Stronger Trend FBRX
Beta / 30D Volatility
Risk Regime
0.33β · 248% Vol 1.09β · 3% Vol Lower Realized Risk FBRX
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 52.7 / 100 (HOLD) Higher Composite FBRX
Trailing 12M Revenue (USD)
Operating Scale
$600,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M EBITDA (-404.5% ROE) -$72M ($7.52 Book/Sh · -62.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FBRX +51.71 pp
LYRA: -62.5% · FBRX: -10.79%
3M Horizon FBRX +108.86 pp
LYRA: -87.62% · FBRX: +21.24%
6M Horizon FBRX +252.17 pp
LYRA: -92.13% · FBRX: +160.04%
1Y Horizon FBRX +235.54 pp
LYRA: -92.85% · FBRX: +142.69%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LYRA Revenue FBRX Revenue LYRA Op. Margin FBRX Op. Margin Margin Leader
FY2017 N/A $0M N/A -91775.6% FBRX
FY2018 N/A $20M N/A -254.2% FBRX
FY2019 N/A $0M N/A -11288.9% FBRX
FY2021 $0M N/A -15303.5% N/A LYRA
FY2022 $0M N/A -4131.0% N/A LYRA
FY2023 $0M N/A -4308.1% N/A LYRA
FY2024 $0M N/A -6280.8% N/A LYRA
FY2025 $0M N/A -7794.5% N/A LYRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FBRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 11.1%
IV Percentile 3rd %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LYRA vs FBRX Key Questions & Quantitative Answers

As of Aug 26, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas FBRX carries 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FBRX leads the Growth & Scale pillar: LYRA posts -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin), compared with FBRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), LYRA cumulative revenue shifted N/A while FBRX shifted N/A. In operating R&D and SG&A reinvestment, LYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FBRX.

LYRA screens cheaper on headline valuation multiples. LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas FBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYRA (-404.5% ROE) versus FBRX (-62.3% ROE) capital efficiency.

In options market volatility and institutional positioning, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk). By comparison, FBRX carries 11.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 3% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Aug 26, 2026. For educational research only; not investment advice.